# Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease

Study · id `cardio:ct-nct06917664` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06917664](<https://clinicaltrials.gov/study/NCT06917664>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06917664

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 220 participants.

## Technical summary

Registry record NCT06917664. Randomized; single masking; primary purpose treatment. Start 2025-06-05 (actual); primary completion 2026-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 220 participants (planned count; ClinicalTrials.gov record NCT06917664, source copy `cardio:ctgov-nct06917664-2025-08-27`, retrieved 2026-10-26)
- Started: 2025-06-05 (actual) (ClinicalTrials.gov record NCT06917664, source copy `cardio:ctgov-nct06917664-2025-08-27`, retrieved 2026-10-26)
- Primary completion: 2026-12 (anticipated) (ClinicalTrials.gov record NCT06917664, source copy `cardio:ctgov-nct06917664-2025-08-27`, retrieved 2026-10-26)
- Completion: 2027-06 (anticipated) (ClinicalTrials.gov record NCT06917664, source copy `cardio:ctgov-nct06917664-2025-08-27`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06917664, source copy `cardio:ctgov-nct06917664-2025-08-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06917664-2025-08-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Treatment of Moderate Ischemic Mitral Regurgitation in Patients With Coronary Artery Disease
- Condition: Coronary Artery Disease
- Condition: Ischemic Mitral Regurgitation
- Condition: Angiotensin Receptor/Neprilysin Inhibitor
- Intervention (Drug): sacubitril/valsartan
- Lead sponsor: China National Center for Cardiovascular Diseases
- Lead sponsor class: OTHER\_GOV
- Collaborator: Chinese Academy of Medical Sciences, Fuwai Hospital
- Collaborator class: OTHER
- Collaborator: Chinese Academy of Medical Sciences
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Sacubitril/valsartan (combination) (`cardio:sacubitril-valsartan`)
- Registry lists this organization as the lead sponsor: China National Center for Cardiovascular Diseases (`cardio:org-china-national-center-for-cardiovascular-diseases`)
- Registry lists this organization as a collaborator: Chinese Academy of Medical Sciences, Fuwai Hospital (`cardio:org-chinese-academy-of-medical-sciences-fuwai-hospital`)

## Provenance

Content hash: 6fc329e24954951a45ac025656bbb76d39dd6851aa81b935fd7ffdd34cbe331e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
